Bisphosphonates (Fosamax) Increases Risk of Femoral Fractures
A recent article in the Journal of the American Medical Association (JAMA) has again linked use of bisphosphonates for osteoporosis to increased risk of subtrochanteric and femur fractures. The drugs in the bisphosphonate family include Fosamax, Boniva, Actonel, Aredia, Zometa, and Reclast.
The JAMA article, entitled “Bisphosphonate Use and the Risk of Subtrochanteric and Femoral Shaft Fractures in Older Women” followed women aged 68 and older in Ontario, Canada, who had bisphosphonate therapy starting between 2002 2008.
While the overall risk of such fractures is low, the authors found that 64% of those with these fractures were women who had taken bisphosphonates for 5 years or more. Other data suggested that 10% of these fractures may have been prevented if no patient received more than 5 years of bisphosphonate exposure.
Click here to read the entire article: Bisphosphonate Use and the Risk of Subtrochanteric and Femoral Shaft Fractures in Older Women
Fosamax, Used to Treat Osteoporosis, Is Linked To Unusual Bone Fractures in The Femur
If you or a loved one have taken Fosamax or another bisphosphonate drug and have suffered these fractures, please click here to speak to a Brandi Law Firm Fosamax Attorney.